Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical SciencesfiledCriticalDow Pharmaceutical Sciences
Priority to ARP080101365priorityCriticalpatent/AR065912A1/en
Publication of AR065912A1publicationCriticalpatent/AR065912A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Reivindicacion 1: El uso de azitromicina para la preparacion de un medicamento para el tratamiento del acné vulgaris nodular, medicamento que se administra en forma sistémica a un individuo que sufre el acné vulgaris nodular en una cantidad ydurante un tiempo suficientes para reducir el numero de nodulos acneicos presentes en la piel del individuo. Reivindicacion 9: El uso de acuerdo con cualquiera de las reivindicaciones 1 a 8, en el cual el medicamento comprende, además deazitromicina, una medicacion que es eficaz para el tratamiento de acné vulgaris. Reivindicacion 10: El uso de acuerdo con la reivindicacion 9, en el cual la medicacion sistémica es isotretinoina.Claim 1: The use of azithromycin for the preparation of a medicament for the treatment of nodular acne vulgaris, a drug that is administered systemically to an individual suffering from nodular acne vulgaris in an amount and for sufficient time to reduce the number of nodules Acneic present in the skin of the individual. Claim 9: The use according to any of claims 1 to 8, wherein the medicament further comprises deazithromycin, a medication that is effective for the treatment of acne vulgaris. Claim 10: The use according to claim 9, wherein the systemic medication is isotretinoin.
ARP0801013652008-04-012008-04-01
AZITROMYCIN FOR THE MODULAR ACNE TREATMENT
AR065912A1
(en)
Topical anhydrous pharmaceutical composition, comprising niacin derivatives and an acceptable carrier, its application allows improved sexual well-being.